Viking Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 26.86 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.43B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c...